![]() Forecast: LLY's Forecast score is 40, which is above the Drug Manufacturers - General industry mean.LLY is passing 0 out of 7 due diligence checks. Financials: LLY's Financials score is 0, which is equal to the Drug Manufacturers - General industry average. ![]() ![]() Valuation: LLY's Valuation score is 0, which is equal to the Drug Manufacturers - General industry average.WallStreetZen was built to help part-time investors perform better fundamental analysis in minutes instead of hours.Įli Lilly & Co is currently passing 11/38 due diligence checks and has average fundamentals. Keep tabs on your LLY investment: Create a watchlist to get live updates on your investment in Eli Lilly & Co stock.Make your LLY buy order: Decide if you will purchase LLY shares at the current market price or use a limit order to buy LLY stock at a given price.Is Eli Lilly & Co stock a good investment? Should you buy shares of LLY? How do LLY's underlying business fundamentals look? Do top analysts think Eli Lilly & Co is a good buy? Why has LLY's stock price moved recently? (Hint: Our stock market analysis website can help you figure out if LLY is a good stock to buy). Evaluate Eli Lilly & Co stock: The Eli Lilly & Co ticker symbol is LLY.Deposit funds into your brokerage account: Choose your payment method and add your info.Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.Figure out where to buy Eli Lilly & Co stock: You need to choose a stock brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you choose where to buy Eli Lilly & Co stock.The company also kicked off the Mounjaro campaign less than a week after finalizing a $630 million deal with Confo Therapeutics for its non-opioid neuropathic pain drug, CFTX-1554. The company’s move was greeted by several stakeholders, including the American Diabetes Association, which called on other drugmakers, namely Sanofi and Novo Nordisk, to follow Lilly’s lead.Īdditionally, to meet the growing demand for its diabetes products, Lilly announced earlier this year that it is investing $50 million into its North Carolina manufacturing facility. Lilly has been busy as of late, outlining a plan to introduce four new drugs this year, including in the diabetes space.Īt the start of the month, Eli Lilly said it would reduce the price of the most commonly prescribed insulins by 70% and cap the monthly out-of-pocket costs at $35 or less. “Because Mounjaro is still a launch product with dynamic demand, some pharmacies may continue to experience intermittent delays from time to time,” Eli Lilly said in an emailed statement to Reuters. Still, despite Mounjaro’s recent return, the pharma company warned that there could be the occasional hiccup down the line. Lilly’s campaign launch also comes weeks after Mounjaro and Trulicity, another diabetes drug, finally returned to shelves following a two-month shortage driven by the high demand for diabetes drugs due to off-label use for weight loss. The drug has been a solid performer for Lilly despite the shortages, producing $482.5 million in revenue last year, according to the company’s latest earnings report. The treatment suppresses appetite and boosts insulin sensitivity. The injection was first approved by the Food and Drug Administration in May 2022 for treating type 2 diabetes in adults. Mounjaro has had a rollercoaster ride in its first year on the market.
0 Comments
Leave a Reply. |